Development and influencing factors of compliance behaviors of investigators in clinical trials

Abstract

The development and influencing factors of compliance behavior of investigators in clinical trials were explored. According to literature review, a hypothetical model of development of compliance behavior of investigators in clinical trials was established, and the influencing factors of compliance behavior of investigators and their interrelationships were studied based on questionnaire survey of five hundred investigators sampled randomly from one hundred clinical trial institutions in China. Cronbach’s alpha coefficient and structural equation modeling were adopted to empirically analyze the results. Six variables in the hypothetical model were included: compliance behavior of investigators, credibility of clinical trial, capability of government regulation, quality control of sponsor, quality control of clinical institution and compliance intention of investigators. Empirical analysis showed that the compliance behavior of investigators in clinical trial was directly affected by compliance intention of investigators, quality control of sponsor and quality control of clinical institution. In addition, credibility of clinical trial and capability of government regulation indirectly affected the compliance behavior of investigators in clinical trial through influencing the compliance intention of investigators, quality control of sponsor and quality control of clinical institution. Quality control of sponsor was affected by credibility of clinical trial and capability of government regulation while quality control of clinical institution was only influenced by capability of government regulation.

Keywords

clinical trials / compliance behavior of investigator / structural equation modeling / questionnaire survey

References

[1] WangZH, YangZJ, DuYP, et al.. Management of compliance of investigators in clinical trials. J Jiangxi Univ TCM (Chinese), 2009, 21(1): 20-22

[2] FuWG. Effectiveness of the compliance behavior: a analysis beyond positive method. Zhejiang Acad J (Chinese), 2010140-149

[3] ZhaoJ, ChangF. Empirical analysis of the influential factors of drug safety risk. Zhongguo Zhi Ye Yao Shi (Chinese), 2012, 9(7): 44-47

[4] KristenPM. Structural equation modeling and rehabilitation research. Am J Phys Med Rehabil, 2000, 79(3): 301-309

[5] ShengY, LiXL. Empirical study on influencing factors of customer loyality in network marketing. Zhongguo Guan Li Xin Xi Hua (Chinese), 2010, 13(6): 112-114

[6] FloydFJ, WidamanKF. Factor analysis in the development and refinement of clinical assessment instruments. Psychol Assess, 1995, 7(3): 286-299

[7] AjzenI. The theory of planned behaviour: reactions and reflections. Psychol Health, 2011, 26(9): 1113-1127

[8] KothandapaniV. Validation of feeling, belief, and intention to act as three components of attitude and their contribution to prediction of contraceptive behavior. J Pers Soc Psychol, 1971, 19(3): 321-333

[9] ZouHS. . Study on commercial bank compliance management, 2007, Beijing, University of International Business and Economics

[10] HortonR. The clinical trial: deceitful, disputable, unbelievable, unhelpful, and shameful—what next. Control Clin Trials, 2001, 22(6): 593-604

[11] Al-MarzoukiS, EvansS, MarshallT, et al.. Are these data real? Statistical methods for the detection of data fabrication in clinical trials. BMJ, 2005, 331(7511): 267-270

[12] RanstamJ, BuyseM, GeorgeSL, et al.. Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. Control Clin Trials, 2000, 21(5): 415-427

[13] ZhaoL. Special supervision of clinical trial will launch soon. Zhong Guo Yi Yao Bao (Chinese), 2009, 15(1): 28-32

[14] DouLF. Discussion on capacity of local government in transitional period. Xue Hai (Chinese), 2002, 2: 46-47

[15] WuXJ, LiX. Development and current situation of clinical trial institution in China. Zhong Guo Yi Yao Jing Ji (Chinese), 2009, 2: 36-41

[16] ZhaoYL, CuiSQ, XuY, et al.. Investigation of problems in implementing drug’s clinical trials in China. Yao Wu Liu Xing Bing Xue Za Zhi (Chinese), 2006, 15(6): 341-367

[17] ZhaoYM. Strategies and methods to improve compliance of subjects in clinical trials. Zhong Hua Yi Xue Za Zhi (Chinese), 2005, 85(23): 1588-1590